Denne tilstand, der kaldes alvorlig neutropeni eller agranulocytose, er forekommet hos 1 ud af 100 mennesker, der har fået Ferriprox ved kliniske forsøg.
This condition, known as severe neutropenia or agranulocytosis, has occurred in about 1 out of 100 people who have taken Ferriprox in clinical studies.